California Institute for Regenerative Medicine Funding Program	9 Months Ended
Sep. 30, 2012
California Institute for Regenerative Medicine Funding Program [Abstract]
California Institute for Regenerative Medicine Funding Program	Note 10. California Institute for Regenerative Medicine Funding Program In July 2012, the California Institute for Regenerative Medicine (CIRM) approved an award to us for up to $20 million under CIRM’s Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of our HuCNS-SC cells in cervical spinal cord injury over a maximum four-year period, with the goal of filing an investigational new drug application (IND) in that time. In September 2012, CIRM approved a second award to us for up to $20 million under RFA 10-05. The award is to fund preclinical development of our proprietary HuCNS-SC cells in Alzheimer’s disease over a maximum four-year period, with the goal of filing an IND in that time. Funding to for-profit companies under RFA 10-05 is expected to be structured as forgivable loans, in accordance with mutually agreed upon terms and conditions and CIRM regulations. As of September 30, 2012, we and CIRM were in discussions regarding the terms and conditions of the funding, and no funds had yet been disbursed to us from CIRM.

California Institute for Regenerative Medicine Funding Program

9 Months Ended

Sep. 30, 2012

California Institute for Regenerative Medicine Funding Program [Abstract]

California Institute for Regenerative Medicine Funding Program

Note 10. California Institute for Regenerative Medicine Funding Program

In July 2012, the California Institute for Regenerative Medicine (CIRM) approved an award to us for up to $20 million under CIRM’s Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of our HuCNS-SC cells in cervical spinal cord injury over a maximum four-year period, with the goal of filing an investigational new drug application (IND) in that time.

In September 2012, CIRM approved a second award to us for up to $20 million under RFA 10-05. The award is to fund preclinical development of our proprietary HuCNS-SC cells in Alzheimer’s disease over a maximum four-year period, with the goal of filing an IND in that time.

Funding to for-profit companies under RFA 10-05 is expected to be structured as forgivable loans, in accordance with mutually agreed upon terms and conditions and CIRM regulations. As of September 30, 2012, we and CIRM were in discussions regarding the terms and conditions of the funding, and no funds had yet been disbursed to us from CIRM.